Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.49 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7002432 | 0.83 | APLNR (0.73) | APLNRCHRM2HTR2AHTR2C | |
| SCHEMBL3264888 | 0.83 | APLNR (0.50) | APLNRKDM1AMAOAMAOBSLC2A1 | |
| SCHEMBL13975424 | 0.81 | ACHE (0.52) | CHRM2SMN1; SMN2MEN1KMT2AKDM4E | |
| SCHEMBL5024499 | 0.80 | ESR1 (0.49) | KDM1AMAOAMAOB | |
| SCHEMBL24067917 | 0.80 | MEN1 (0.43) | CHRM2SMN1; SMN2MEN1KMT2AKDM4E | |
| SCHEMBL26028290 | 0.79 | APLNR (0.46) | APLNRKDM1AMAOAMAOBSLC2A1 | |
| SCHEMBL11224282 | 0.79 | ESR1 (0.47) | HTTMEN1KMT2A | |
| SCHEMBL17138360 | 0.79 | APLNR (0.71) | APLNRCHRM2HTR2AHTR2C | |
| SCHEMBL19954239 | 0.78 | ADRB2 (0.51) | APLNRCHRM2MAPK1HTTSMN1; SMN2 | |
| SCHEMBL3265276 | 0.77 | SLC2A1 (0.57) | APLNRKDM1AMAOASLC2A1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120004262-A1 | PHENYLCYCLOPROPYLAMINE DERIVATIVES AND THEIR MEDICAL USE | ORYZON GENOMICS, S.A. (ES) | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004262-A1 | PHENYLCYCLOPROPYLAMINE DERIVATIVES AND THEIR MEDICAL USE | PNMT, ABCB1, SNCA | APLNR 1155/4885KDM1A 1515/4885MAOA 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.